gefitinib has been researched along with platinum in 14 studies
Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (platinum) | Trials (platinum) | Recent Studies (post-2010) (platinum) |
---|---|---|---|---|---|
5,231 | 566 | 2,919 | 11,422 | 457 | 6,106 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (14.29) | 29.6817 |
2010's | 10 (71.43) | 24.3611 |
2020's | 2 (14.29) | 2.80 |
Authors | Studies |
---|---|
Azzariti, A; Colucci, G; Lu, B; Paradiso, A; Severino, M; Xu, JM | 1 |
Gadgeel, SM; Heath, EI; Heilbrun, LK; Ruckdeschel, JC; Venkatramanamoorthy, R; Wozniak, A | 1 |
Fan, Y; Huang, ZY; Luo, LH; Yu, HF | 1 |
Murphy, M; Stordal, B | 1 |
Saijo, N | 1 |
Douillard, JY; Jiang, GL; Kim, ES; Li, LY; Liao, ML; Milenkova, T; Sun, Y; Wu, YL | 1 |
Ji, L; Pei, Y | 1 |
Akamatsu, H; Inoue, A; Kobayashi, K; Mitsudomi, T; Mori, K; Nakagawa, K; Nakanishi, Y; Nukiwa, T; Yamamoto, N | 1 |
Gan, B; Huang, Y; Liao, R; Lou, N; Wu, Y; Xu, C; Yan, H; Yang, J; Yang, X; Yang, Y; Zhou, Q | 1 |
Hsiue, TR; Hwang, JS; Lai, WW; Lin, CK; Su, WC; Wang, JD; Yang, SC | 1 |
Huo, Z; Jiang, SY; Wang, MZ; Xu, Y; Zhang, J; Zhao, J; Zhong, W | 1 |
Ahn, MJ; Cho, BC; Jang, JS; Jung, I; Kim, DW; Kim, HR; Kim, JH; Kim, SW; Lee, DH; Lee, KH; Sun, JM | 1 |
Ishiki, H; Kiuchi, D; Kubo, E; Satomi, E; Shimizu, M; Tanaka, T; Yokota, S | 1 |
Abbie, E; Boyne, DJ; Brenner, DR; Cheung, WY; Eaton, K; Elia-Pacitti, J; Ewara, EM; Gogna, P; Hu, LXY; Jarada, TN; O'Sullivan, DE; Pabani, A; Rose, JB; Yusuf, A | 1 |
4 review(s) available for gefitinib and platinum
Article | Year |
---|---|
Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Clinical Trials as Topic; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Dosage; Gene Expression; Humans; Lung Neoplasms; Mutation; Ovarian Neoplasms; Platinum; Protein Kinase Inhibitors; Quinazolines; Recurrence; Survival Rate; Treatment Outcome | 2011 |
Problems involved in the clinical trials for non-small cell lung carcinoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Maintenance Chemotherapy; Mutation; Patient Selection; Pemetrexed; Platinum; Quinazolines | 2012 |
Interstitial lung disease associated with gefitinib in Japanese patients with EGFR-mutated non-small-cell lung cancer: combined analysis of two Phase III trials (NEJ 002 and WJTOG 3405).
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; ErbB Receptors; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Mutation; Platinum; Protein Kinase Inhibitors; Quinazolines; Smoking | 2013 |
Small-Cell Lung Cancer Transformation in Patients With Pulmonary Adenocarcinoma: A Case Report and Review of Literature.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Fatal Outcome; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pemetrexed; Platinum; Quinazolines; Small Cell Lung Carcinoma | 2016 |
5 trial(s) available for gefitinib and platinum
Article | Year |
---|---|
Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC).
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Celecoxib; Confidence Intervals; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Platinum; Probability; Pyrazoles; Quinazolines; Risk Assessment; Sulfonamides; Survival Analysis | 2007 |
[Efficacy of salvage chemotherapy in the advanced non-small cell lung cancer patients who failed the treatment of chemotherapy and EGFR-TKI].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Pemetrexed; Platinum; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Salvage Therapy; Taxoids; Treatment Failure | 2010 |
[Prospective study on surface-enhanced laser desorption/ionization protein fingerprinting for diagnosing gene polymorphism leading to drug resistance drift: sequential therapy with a platinum-based regimen and gefitinib for non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Polymorphism, Genetic; Prospective Studies; Proteomics; Quinazolines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Treatment Outcome | 2013 |
[Efficacies of gefitinib versus paclitaxel/carboplatin for patients with advanced pulmonary adenocarcinoma].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Asian People; Carboplatin; Disease-Free Survival; Gefitinib; Hospitals, General; Humans; Lung Neoplasms; Paclitaxel; Platinum; Quinazolines; Smoking | 2014 |
A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Quinazolines | 2017 |
5 other study(ies) available for gefitinib and platinum
Article | Year |
---|---|
Characterization of sequence-dependent synergy between ZD1839 ("Iressa") and oxaliplatin.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; DNA Adducts; Drug Synergism; ErbB Receptors; gamma-Glutamyltransferase; Gefitinib; HT29 Cells; Humans; Organoplatinum Compounds; Oxaliplatin; Phosphorylation; Platinum; Quinazolines | 2003 |
[Efficacy and safety of gefitinib or docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who had failed previous platinum-based first-line chemotherapy].
Topics: Adult; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Docetaxel; Exanthema; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Neutropenia; Platinum; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Remission Induction; Retrospective Studies; Survival Rate; Taxoids | 2011 |
Health-related quality of life after first-line anti-cancer treatments for advanced non-small cell lung cancer in clinical practice.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Platinum; Prospective Studies; Quality of Life; Quinazolines; Sickness Impact Profile; Surveys and Questionnaires; World Health Organization | 2016 |
Is Gefitinib Combined With Platinum-Doublet Chemotherapy a Counterpart to Osimertinib Monotherapy in Advanced
Topics: Acrylamides; Aniline Compounds; Carboplatin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Pemetrexed; Platinum | 2020 |
Prevalence, Treatment Patterns, and Outcomes of Individuals with
Topics: Afatinib; Alberta; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Humans; Lung Neoplasms; Mutation; Platinum; Prevalence | 2022 |